Co-Diagnostics, Inc.

Co-Diagnostics, Inc. Earnings Recaps

CODX Health Care 2 recaps
Q1 2026 May 16, 2026

Shares of Co-Diagnostics plunged 19.7% post-earnings as investors reacted negatively to the cautious outlook and apparent deceleration in key market opportunities, despite ongoing pipeline progress. The market dismissed management’s optimism about regulatory filings and international expansion in favor of near-term commercialization uncertainties.

Key takeaways
  • Clinical study enrollment for the upper respiratory multiplex test completed with over 1,400 patients, but lower-than-expected COVID prevalence delayed broader submission, now focusing initially on Flu A, Flu B, and RSV only.
  • FDA 510(k) submission targeted for Q3 2026, contingent on internal validation and regulatory review, with commercialization still pending.
  • Expansion in India via CoSara JV reached regulatory milestones (CDSCO license for local manufacturing) and a larger $13B addressable market, but strategic alternatives including a SPAC remain uncertain with no confirmed transaction.
  • TB clinical studies scheduled to begin soon in India, targeting a significant market opportunity but still in early validation stages.
  • Progress in Saudi Arabia's CoMira joint venture noted but lacks concrete timelines or near-term revenue impact.
Full recap
Q3 2025 Nov 15, 2025

Co-Diagnostics reported significant progress in Q3 2025, highlighting strategic partnerships and initiatives aimed at enhancing operational capabilities and expanding its international footprint.

Key takeaways
  • Initiation of a SPAC transaction potentially unlocking substantial value from the CoSara Diagnostics joint venture in India.
  • Launch of CoMira joint venture with Arabian Eagle to localize and distribute the Co-Dx PCR platform across 19 countries in the MENA region.
  • Focus on innovation through its AI business unit, enhancing operational efficiency and opening new market opportunities.
  • The company is poised for growth with strategic financial maneuvers aimed at solidifying its balance sheet as it prepares for commercialization in 2026.
Full recap